# Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.

> PubMed lists PMID 37325898 in Future cardiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-16 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37325898-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37325898-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-37325898-elamipretide-v1.json
- Content SHA-256: `b345d298bfc010cf8d8978ff3abfce92a1289f2384b642335f830b20363bddef`

## Claims and source pins

### Headline

Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide. ([`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`](#source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce))

### Summary

PubMed lists PMID 37325898 in Future cardiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-16 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`](#source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce))

### Paragraph 1

PubMed lists PMID 37325898 in Future cardiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-16 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`](#source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`](#source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce))

## Sources

<a id="source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce"></a>
- **Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide. · retained source version 1:2026-01-27:current:ef04fef6bbce780c54d2423f0287143002ff5923f9b441943d7d0b72788af6cf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37325898/) (`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-37325898-elamipretide-v1.json SHA-256: b345d298bfc010cf8d8978ff3abfce92a1289f2384b642335f830b20363bddef.